Mineralys Therapeutics, Inc. Common Stock (MLYS)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$15.33

+0.09 (+0.59%)

Market Cap: $1.35B

Last updated: Nov 06, 2026 at 4:20 PM ET

Earnings

Performance (10Y)

Beat Rate

56%(9/16)

Avg Surprise

-14.13%

Upcoming Estimates

Period ending Dec 31, 2026

EPS Consensus$-2.92

Range$-3.12 - $-2.42

8 analysts

Revenue Consensus

Range$0 - $0

8 analysts

Last 12 of 16 reported quarters and 1 upcoming estimate

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-2.92	$-3.12 - $-2.42	-	-	8	-	-
Sep 30, 2026Sep 26 Reported Nov 4, 2026Reported Nov 4	$-0.64	$-0.53	$-0.60 - $-0.39	-20.75%	Miss	8	4 2 30d	-23.1%
Jun 30, 2026Jun 26 Reported Aug 12, 2026Reported Aug 12	$-2.85	$-0.57	$-0.61 - $-0.44	-400.00%	Miss	8	0 5 30d	-331.8%
Mar 31, 2026Mar 26 Reported May 6, 2026Reported May 6	$-0.47	$-0.44	$-0.48 - $-0.38	-6.82%	Miss	6	3 0 30d	+40.5%
Dec 31, 2025Dec 25 Reported Mar 12, 2026Reported Mar 12	$-0.40	N/A	-	+57.45%	Beat	8	1 0 30d	+59.2%
Sep 30, 2025Sep 25 Reported Nov 10, 2025Reported Nov 10	$-0.52	$-0.61	$-0.70 - $-0.51	+14.75%	Beat	7	6 1 30d	+54.0%
Jun 30, 2025Jun 25 Reported Aug 12, 2025Reported Aug 12	$-0.66	$-0.74	$-0.74 - $-0.60	+10.81%	Beat	7	3 1 30d	+20.5%
Mar 31, 2025Mar 25 Reported May 12, 2025Reported May 12	$-0.79	$-0.98	$-1.14 - $-0.80	+19.39%	Beat	5	1 1 30d	-12.9%
Dec 31, 2024Dec 24 Reported Feb 12, 2025Reported Feb 12	$-0.98	$-1.08	$-1.20 - $-0.68	+9.26%	Beat	7	0 7 30d	-60.7%
Sep 30, 2024Sep 24 Reported Nov 11, 2024Reported Nov 11	$-1.13	$-0.83	$-0.93 - $-0.66	-36.14%	Miss	7	No revisions (30d)	-98.2%
Jun 30, 2024Jun 24 Reported Aug 13, 2024Reported Aug 13	$-0.83	$-0.70	$-0.84 - $-0.65	-18.57%	Miss	7	No revisions (30d)	-167.7%
Mar 31, 2024Mar 24 Reported May 9, 2024Reported May 9	$-0.70	$-0.67	$-0.81 - $-0.51	-4.48%	Miss	5	No revisions (30d)	-37.3%
Dec 31, 2023Dec 23 Reported Mar 21, 2024Reported Mar 21	$-0.61	$-0.82	$-1.06 - $-0.55	+25.61%	Beat	4	No revisions (30d)	+64.9%

Key Metrics

Valuation
P/E Ratio	-3.52	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	0.00%
ROE	-80.90%	ROIC	-51.14%
Financial Health
Debt/Equity	0.20x	Interest Coverage	N/A
Current Ratio	11.83x	Quick Ratio	11.83x
Trading Statistics
Beta	0.82	Avg Volume	1.84M
52-Week High	$47.65	52-Week Low	$15.15

Technical Indicators Dashboard

Moving Averages

SMA 10$18.16

SMA 20$19.66

SMA 50$23.78

SMA 200$26.58

EMA 10$17.57

EMA 20$19.36

EMA 50$22.30

EMA 200$25.92

MACD

Line: -2.18Signal: -1.78Hist: -0.40

ADX

ADX: 28.8+DI: 17.4-DI: 32.8

Aroon & PSAR

Aroon UpN/A

Aroon Down100.0

PSAR$20.83

Bollinger Bands

Upper Band$24.51

Lower Band$14.81

%B Position4934%(Upper)

Band Width0.05

RSI (14-Day)

Oversold

28.7

Momentum Oscillators

Stoch %K9.9

Stoch %D10.9

Williams %R-95.0

ROC (10d)-25.4%

Momentum-5.22

CCI (20d)-152.6

MFI (14d)40.9

Volatility Measures

ATR (14d)$1.46(9.5%)

StdDev (20d)2.42

Hist Vol94.0%(High)

Volume Flow

VWAP$15.31

OBV-2.7K

AD Line16.5M

CMF (20d)-0.260

Volume Metrics

Avg Vol (20d)1.9M

Vol Ratio0.7x

VWMA (20d)$18.94

Pivot Points

R3$19.39

R2$18.53

R1$16.88

Pivot Point$16.02

S1$14.37

S2$13.51

S3$11.86

Advanced Oscillators

TSI-37.33

Ultimate Osc27.2

KST-248.62

Financial Data

Quarter	Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023
Total Revenue	$0	$0	$0	$0	$0	$0	$0	$34,000	$0	$0	$0	$0
Cost of Revenue	$0	$0	$0	$13,000	$0	$0	$0	$17,000	$0	$0	$0	N/A
Gross Profit	$0	$0	$0	$-13,000	$0	$0	$0	$17,000	$0	$0	$0	N/A

Operating Expenses	$60.09M	$246.04M	$45.34M	$38.28M	$41.13M	$46.75M	$44.45M	$51.77M	$60.11M	$45.17M	$35.36M	$27.71M
R&D	$22.67M	$221.38M	$24.36M	$24.40M	$31.45M	$38.28M	$37.88M	$44.57M	$53.98M	$39.27M	$30.75M	$23.68M
SG&A	$37.42M	$24.66M	$20.98M	$13.88M	$9.68M	$8.47M	$6.57M	$7.20M	$6.12M	$5.89M	$4.61M	$4.03M
Operating Income	$-60,087,000	$-246,040,000	$-45,340,000	$-38,280,000	$-41,131,000	$-46,746,000	$-44,447,000	$-51,767,000	$-60,106,000	$-45,168,000	$-35,362,000	$-27,711,000

Interest Income	$5.95M	$4.96M	$6.00M	$6.04M	$4.20M	$3.47M	$2.24M	$2.81M	$3.77M	$4.15M	$3.85M	$3.32M
Interest Expense	$3.19M	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Income Before Tax	$-57,328,000	$-241,071,000	$-39,339,000	$-32,234,000	$-36,932,000	$-43,274,000	$-42,211,000	$-48,946,000	$-56,342,000	$-41,014,000	$-31,508,000	$-24,389,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-57,328,000	$-241,071,000	$-39,339,000	$-32,234,000	$-36,932,000	$-43,274,000	$-42,211,000	$-48,946,000	$-56,342,000	$-41,014,000	$-31,508,000	$-24,389,000

EBITDA	$-64,229,000	$-250,539,000	$-49,954,000	$-42,474,000	$-43,512,000	$-48,961,000	$-45,481,000	$-53,077,000	$-62,817,000	$-48,004,000	$-37,862,000	$-29,777,000
EBIT	$-60,087,000	$-246,027,000	$-45,335,000	$-38,279,000	$-41,131,000	$-46,748,000	$-44,450,000	$-51,755,000	$-60,116,000	$-45,166,000	$-35,361,000	$-27,711,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about MLYS

News

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Mineralys Therapeutics, Inc. announced inducement stock option and restricted stock unit awards to a new non-executive employee on November 3, 2026. These awards, covering 14,880 shares and 11,160 shares respectively...

Yahoo Finance Singapore•Nov 6, 2026 12:00 AM ET11/6/26•Somewhat-Bullish

Mineralys Therapeutics, Inc. (MLYS) Tops Q3 EPS by 11c

Mineralys Therapeutics, Inc. (MLYS) announced its Q3 earnings, reporting an EPS of ($0.64). This figure was $0.11 better than the analyst consensus estimate of ($0.75). The company's stock price currently stands at...

StreetInsider•Nov 5, 2026 6:41 AM ET11/5/26•Bullish

Mineralys Therapeutics Inc (MLYS) Q3 2026 Earnings Call Highlights: Strong Phase 3 Data and ...

Mineralys Therapeutics Inc. reported strong Phase 3 data for lorundrostat in its Q3 2026 earnings call, showing robust efficacy in blood pressure reduction and a favorable safety profile. The company is well into...

Yahoo Finance Singapore•Nov 5, 2026 2:41 AM ET11/5/26•Somewhat-Bullish

Mineralys Therapeutics Q3FY27 Results: Net loss widens to $57.3 million

Mineralys Therapeutics reported a significant widening of its net loss to $57.3 million in Q3 2026, primarily due to increased commercialization expenses for its lead candidate...

scanx.trade•Nov 5, 2026 1:22 AM ET11/5/26•Somewhat-Bearish

Mineralys Therapeutics Announces Derek DiRocco's Board Resignation Effective December 31 and Q3 2026 Financial Results

Mineralys Therapeutics, Inc. announced the resignation of board member Derek DiRocco, Ph.D., effective December 31, 2026. The company stated that his departure was not due to any disagreements. Additionally...

Kalkine Media•Nov 4, 2026 11:41 PM ET11/4/26•Neutral

MLYS Valuation and Fair Value

P/E: -3.5x
P/B: 2.7x

See GNG's fair value

MLYS Profitability: Margins, ROIC and FCF

Operating margin: 0.0%
Net margin: 0.0%
ROIC: -51.1%
ROE: -80.9%

MLYS Competitors

Company	Ticker
Eton Pharmaceuticals Inc	ETON
STAAR Surgical Company	STAA
Structure Therapeutics Inc. American Depositary Shares	GPCR
Taysha Gene Therapies Inc	TSHA
Kalvista Pharmaceuticals Inc	KALV
Opko Health Inc	OPK
Cronos Group Inc	CRON
Alpha Tau Medical Ltd	DRTS

Sector: Healthcare

MLYS Analyst Ratings

Consensus: Buy
Analysts: 10
Strong Buy: 0
Buy: 9
Hold: 1
Sell: 0
Strong Sell: 0

MLYS Bull Case vs Bear Case

Bull case

90.0% of MLYS's analyst ratings are Buy or Strong Buy.

MLYS Earnings: Beat Rate and Next Report

Beat rate: 5 of 8 quarters (62.5%)
Average surprise: -39.5%
EPS estimate (fiscal period ending Dec 31, 2026): $-2.92

MLYS Earnings Date

MLYS reports Mar 10, 2027, before the open. The date is estimated.

MLYS Earnings Call

The latest MLYS earnings call transcript on file is labeled 2026Q2.

Read the 2026Q2 transcript

MLYS ETF Holders

GNG tracks 9 ETFs that hold MLYS. The largest weights:

State Street SPDR S&P Biotech ETF (XBI), 0.31% of the fund
iShares Biotechnology ETF (IBB), 0.09% of the fund
Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.06% of the fund
Fidelity Enhanced Small Cap Core ETF (FESM), 0.05% of the fund
iShares Russell 2000 ETF (IWM), 0.05% of the fund

Open the ETF Stock Exposure tool for MLYS

Frequently Asked Questions About MLYS

When does MLYS report earnings?

Mineralys Therapeutics, Inc. Common Stock (MLYS) is expected to report earnings on Mar 10, 2027.

Does MLYS pay dividends?

Mineralys Therapeutics, Inc. Common Stock (MLYS) does not currently pay a regular dividend.

What is MLYS's market cap?

Mineralys Therapeutics, Inc. Common Stock (MLYS) has a market capitalization of $1.35B with a current stock price of $15.33.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In